Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Clin Rheumatol. 2011 Feb 22;30(6):849–853. doi: 10.1007/s10067-011-1710-9

Table 1.

Outcomes and treatment of the 16 patients with active leg ulceration

Patient no. DAS-28 at ulcer development DAS-28 at healing or most recent visit Remission (+/−) Medication
Ulcer outcome Follow-up duration (months) Total time to ulcer healing Time to ulcer healing after starting DMARD or anti-TNF therapy
HCQ Non-biol DMARD Steroid Anti-TNF
1 6.99 7.47 + + + Not healed 20.4
2 1.47 1.44 + + + + + Not healed 30.6 No response
3 2.02 1.79 + + + + Healed 22.3 22.3 4
4 7.52 2.86 + + + Healed 16.3 16.3 4
5 5.89 2.73 + + + Not healed 19.0
6 3.03 3.03 + + + + + Amputated 9.8 9.8 1
7 4.07 2.30 + + Not healed 5.7
8 3.16 3.50 + + Not healed 1.5
9 7.53 7.75 + Not healed 45.7
10 1.40 1.86 + + + + Healed 10.6 10.6 1
11 2.46 2.46 + Not healed 2.0
12 2.91 2.55 + + + Healed 21.1 21.1 3.5
13 2.80 1.59 + + + + Healed 116.3 116.3 116.3
14 3.62 3.62 + Died 3.1
15 2.67 2.60 + + Not healed 17.0
16 7.99 7.99 + Not healed 3.0

HCQ hydroxychloroquine, Non-biol DMARD non-biologic disease modifying antirheumatic drug, Anti-TNF anti-tumor necrosis factor-α agent